FDA Approval of Wegovy® for MASH: Strategic Implications for the Next Phase of the Metabolic Disease Market

The FDA approval of Wegovy® (semaglutide) for MASH with moderate-to-advanced fibrosis marks a pivotal milestone in metabolic disease treatment, expanding GLP-1 therapies beyond obesity and diabetes. This approval reshapes the competitive landscape, placing greater emphasis on market access, real-world evidence, biomarker-driven patient identification, and commercialization strategies over clinical efficacy alone.